Saracatinib_379231-04-6_DataSheet_MedChemExpress

Product Name:

Saracatinib CAS No.:

379231-04-6Cat. No.:

HY-10234MWt:

542.03Formula:

C27H32ClN5O5Purity :>98%

Solubility:Mechanisms:

Biological Activity:

References:

Caution: Not fully tested. For research purposes only

Medchemexpress LLC

https://www.wendangku.net/doc/3c8901433.html,

[1]. Chang YM, Src family kinase oncogenic potential and pathways in prostate cancer as revealed by

AZD0530. Oncogene, 2008, 27(49), 6365-6375.[2]. Green TP, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol, 2009,

3(3), 248-261.[3]. Purnell PR, et al. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung

cancer cells. J Thorac Oncol, 2009, 4(4), 448-454.Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr

and Lck; less active for Abl and EGFR (L858R and L861Q).

IC50 value: 2.7 nM(c-Src); 30 nM (v-Abl) [1]

Target: c-Src; v-Abl in vitro: Saracatinib also potently inhibits other Src tyrosine kinase family members including c-Yes, Fyn, Lyn,Blk, Fgr, and Lck with IC50 from 4-10 nM. Saracatinib sensitively inhibits Src Y530F NIH 3T3 with IC50 of 80nM. Saracatinib signi?cantly impairs the invasion of HT1080 cells through a 3-dimensional collagen matrix and completely inhibits EGF-induced cell scattering in NBT-II bladder cancer cells [1]. Saracatinib potent inhibits Src activation in DU145 and PC3 cells, which through inhibition of Y419 phosphorylation. Saracatinib inhibits the growth of prostate cancer including PC3, DU145, CWR22Rv1 and LNCaP, while Saracatinib show...

Pathways:Protein Tyrosine Kinase/RTK; Target:Src Product Data Sheet

DMSO54 mg/ml

18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A

E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m